Child Psychiatry (F8-9)

Attention-deficit Hyperactivity Disorder

Attention-deficit hyperactivity disorder is a neurodevelopmental disorder characterized by persistent patterns of inattention, hyperactivity, and impulsivity that impair functioning across multiple settings.

2. Epidemiology

3. Risk Factors

Think of ADHD risk factors in a biopsychosocial framework, but the biological factors dominate:

4. Anatomy and Neurobiological Basis

Understanding the anatomy helps everything else make sense — the clinical features, the pharmacology, and the comorbidities.

5. Classification

6. Clinical Features

The cardinal features of ADHD can be organised into three domains: inattention, hyperactivity, and impulsivity. These must be:

  • Pervasive (across situations) — not just at school or just at home [2]
  • Early onset (< 6y in ICD-10, < 12y in DSM-5) [2]
  • Developmentally inappropriate — beyond what is expected for the child's age and IQ
  • Causing functional impairment in ≥ 2 settings

6.5 Clinical Features by Developmental Stage

Understanding how ADHD manifests across the lifespan is crucial:

Differential Diagnosis of ADHD

Getting the differential diagnosis right in ADHD is absolutely crucial — and it's one of the trickiest areas in child psychiatry. Why? Because many diagnostic criteria of ADHD overlap with other comorbidities [2]. Inattention, restlessness, distractibility, and impulsivity are non-specific symptoms that appear across a wide range of psychiatric, neurodevelopmental, and medical conditions. Your job on the ward (and in the exam) is to parse out what is driving the symptom.

The golden rules for differentiating ADHD from its mimics:

  1. Pervasiveness: ADHD symptoms occur across all settings (home, school, social). If symptoms only appear in one context, think of something else.
  2. Developmental onset: ADHD is early onset (before age 12 in DSM-5, before age 6 in ICD-10). If a previously well child suddenly develops "ADHD-like" symptoms at age 14, think mood disorder, substance use, or trauma.
  3. Course: ADHD is chronic and trait-like — present every day since early childhood. If symptoms are episodic, think bipolar, depression, or substance use.
  4. Context of the inattention: Is the child distracted by external stimuli and novel activities (→ ADHD) or by internal worries (→ anxiety) or by low mood and anhedonia (→ depression)?

References

[1] Senior notes: ryanho-psych.md (Section 12.3 — summary table of childhood psychiatric disorders) [2] Senior notes: ryanho-psych.md (Section 12.3 — Attention-deficit Hyperactivity Disorder, including D/dx table and clinical features) [3] Senior notes: ryanho-psych.md (Section 7.1.2 — Approach to Elated or Irritable Mood; and Bipolar Disorder differential diagnosis of ADHD); Lecture slides: GC 163. I am a superman Bipolar disorder.pdf (p10 — Differential diagnosis of manic episode)

Diagnostic Criteria

ADHD is a clinical diagnosis — there is no blood test, no brain scan, no single questionnaire that "confirms" it. The diagnosis rests on a careful clinical assessment demonstrating that the patient meets standardised criteria. Let me walk you through both the DSM-5 and ICD-10/ICD-11 criteria, explain the reasoning behind each criterion, and then detail the full assessment algorithm and investigation modalities.

DSM-5 Diagnostic Criteria (Attention-Deficit/Hyperactivity Disorder)

The DSM-5 criteria are the most widely used globally and are the standard for clinical practice and research. I'll present each criterion and explain why it exists [2].

Criterion A — Symptom Domains

A persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development, with ≥ 6 of the following criteria persisting for ≥ 6 months to a degree that is inconsistent with developmental level and that directly negatively impacts social and academic/occupational activities. (≥ 5 criteria if age ≥ 17y) [2]

Why ≥ 6 months? — To ensure the symptoms are persistent and not transient reactions to stressors (e.g., a child who is temporarily inattentive after parental divorce). Six months is long enough to distinguish a trait from a state.

Why "inconsistent with developmental level"? — A 3-year-old who can't sit still for 30 minutes is normal. A 10-year-old who can't sit still for 5 minutes is not. The same behaviour has different diagnostic significance depending on age.

Why ≥ 5 (instead of ≥ 6) for ages ≥ 17? — Adults have developed compensatory strategies and the expression of symptoms evolves. A lower threshold acknowledges that fewer overt symptoms may still cause significant impairment in the more demanding adult environment.

Diagnostic Algorithm

Step-by-Step Clinical Assessment Pathway

The assessment of ADHD follows a systematic pathway. Let me lay this out as a practical clinical algorithm:

Detailed Assessment Components

Investigation Modalities

Management of ADHD

Stepwise Approach by Severity and Age

Step 1: By Age Group

Pharmacological Management

Medications: very effective (most effective among all psychotropics) → more effective than psychosocial treatment [2]

This is a remarkable statement and worth emphasising: ADHD medications have among the largest effect sizes of any psychotropic medication in all of psychiatry. Stimulants for ADHD (effect size ~1.0) are more effective than SSRIs for depression (effect size ~0.3–0.5), antipsychotics for schizophrenia (effect size ~0.5), or lithium for bipolar disorder.

A. Stimulants (First-Line)

B. Non-Stimulants (Second-Line)

Non-Pharmacological Management

Non-pharmacological interventions [2]:

References

[2] Senior notes: ryanho-psych.md (Section 12.3 — Attention-deficit Hyperactivity Disorder: management approach, medications, non-pharmacological interventions; Section 12.4 — ODD/CD management including treatment of comorbid ADHD)

Complications of ADHD

Complications of ADHD can be understood at two levels: (1) complications of the disease itself (untreated or undertreated ADHD leading to cascading functional impairment) and (2) complications of treatment (adverse effects of pharmacotherapy). Both are commonly tested and clinically important.

The overarching concept: ADHD is not just "fidgeting and daydreaming." It is a chronic neurodevelopmental condition whose consequences compound over time. The executive dysfunction at its core — impaired inhibition, working memory, planning, and delay tolerance — ripples outward to affect every domain of life. Think of it as a pebble dropped in a pond: the initial neurobiological deficit sends waves through academics, social relationships, self-esteem, family dynamics, occupation, and physical safety, growing wider with each developmental stage.


1. Complications of Untreated / Undertreated ADHD

The notes explicitly organise functional impairment by developmental stage [2]:

2. Complications of Treatment

References

[2] Senior notes: ryanho-psych.md (Section 12.3 — Attention-deficit Hyperactivity Disorder: clinical features and functional impairment, course and prognosis, medications and side effects; Section 12.4 — ODD/CD course and prognosis)

High Yield Summary

  1. Definition: ADHD is a neurodevelopmental disorder of inattention ± hyperactivity-impulsivity, pervasive across settings, with early onset (< 12y DSM-5, < 6y ICD-10), causing functional impairment.

  2. Epidemiology: 2nd commonest childhood psychiatric disorder; M > F (3:1); prevalence ~5–7% in children; ~50% comorbid with other disorders (ODD ~40%, CD ~20%, learning disorders ~25%, anxiety ~25%, mood ~20%).

  3. Pathophysiology: Hypoactive dopamine and noradrenaline in fronto-striatal and mesolimbic circuits → executive dysfunction (poor inhibition, working memory, attention) + delay aversion.

  4. Genetics: Heritability ~70–80%; polygenic; involves dopamine and serotonin system genes.

  5. Neuroimaging: ↓ Volume in basal ganglia and PFC; delayed cortical maturation; disrupted fronto-striatal connectivity.

  6. Three symptom domains: Inattention (presents later, most persistent), Hyperactivity (presents first, improves most with age), Impulsivity (intermediate trajectory).

  7. Lifespan: Hyperactivity > impulsivity > inattention in age-dependent improvement; ~50% retain criteria in adolescence; ~40–60% have adult functional impairment.

  8. ICD-10 vs DSM-5: ICD-10 (Hyperkinetic Disorder, F90) requires BOTH inattention + hyperactivity; DSM-5 allows EITHER domain; ICD-11 has aligned with DSM-5.

  9. Key comorbidity to remember: ADHD + CD = worst prognosis (antisocial trajectory, substance abuse, criminality).

  10. Adult ADHD: Presents differently — internalised restlessness, procrastination, poor time management, relationship instability, low frustration tolerance.

High Yield Summary

  1. ADHD symptoms are non-specific — inattention, hyperactivity, and impulsivity appear in many conditions. Always consider the differential systematically.

  2. The 3 golden rules for ADHD diagnosis over mimics: (a) Pervasive across ≥ 2 settings, (b) Early onset (before age 12), (c) Chronic/trait-like (not episodic).

  3. ADHD vs ODD: "Can't do it" (executive dysfunction) vs "Won't do it" (defiance). Co-occur in ~40%.

  4. ADHD vs Anxiety: Distracted by external stimuli (ADHD) vs internal worries (anxiety).

  5. ADHD vs Depression: Lifelong since childhood (ADHD) vs later onset and episodic (depression). Both impair concentration but via different mechanisms.

  6. ADHD vs Mania: Chronic trait-like course (ADHD) vs episodic with elated mood, grandiosity, ↓ need for sleep, flight of ideas (mania). ADHD should NOT have grandiosity or ↓ need for sleep.

  7. ADHD vs ASD: Wants to socialise but fails due to impulsivity (ADHD) vs fundamental deficit in social reciprocity (ASD). Can co-occur.

  8. ADHD vs Learning Disorder/ID/Gifted: Symptoms only during academic tasks (learning disorder) vs pervasive (ADHD).

  9. ADHD vs Substance Abuse: Symptoms only in context of substance use (SA) vs lifelong (ADHD). Both can co-exist.

  10. Always exclude medical causes: Thyroid, sleep disorders, sensory impairment, seizures, lead exposure.

High Yield Summary

  1. ADHD is a clinical diagnosis — no single test confirms it. Diagnosis requires integration of clinical interview, collateral history from multiple informants, rating scales, developmental history, and exclusion of differential diagnoses.

  2. DSM-5 Criteria: ≥ 6/9 symptoms (≥ 5 if age ≥ 17) in inattention and/or hyperactivity-impulsivity; ≥ 6 months duration; onset before age 12; present in ≥ 2 settings; functional impairment; not better explained by another disorder.

  3. ICD-10 (Hyperkinetic Disorder): Stricter — requires BOTH inattention AND hyperactivity; onset before age 6. ICD-11 has aligned with DSM-5.

  4. Rating scales (Conners, SNAP-IV, SDQ): Supportive but NOT diagnostic on their own. Need parent AND teacher versions to confirm pervasiveness.

  5. Investigations are to exclude mimics and establish pre-treatment baselines: TFTs (thyroid), FBC + iron (deficiency → ↓ dopamine), lead level, audiometry/vision, ECG (pre-stimulant).

  6. Neuropsychological testing: Not routine. Useful for ambiguous cases, comorbid learning disorders, educational accommodations. Classic ADHD profile: low working memory + processing speed indices relative to full-scale IQ.

  7. Pre-treatment baselines: Height, weight, BP, HR, ECG (if cardiac risk factors), LFTs (if starting atomoxetine).

  8. Multiple informant approach: ALWAYS get information from parents AND teachers — you need to confirm pervasiveness across settings.

  9. Adult ADHD: Requires retrospective confirmation of childhood onset; threshold lowered to ≥ 5 symptoms for age ≥ 17; use DIVA or ASRS for structured assessment.

  10. Key difference between ICD-10 and DSM-5: ICD-10 requires both domains + onset < 6y (stricter); DSM-5 allows either domain + onset < 12y (broader). ICD-11 now aligns with DSM-5.

High Yield Summary

  1. Multimodal approach: ADHD management requires individualised combination of psychoeducation, behavioural therapy, medication, and school accommodations.

  2. Age-based strategy: Pre-school → behavioural therapy first. School-age mild → watchful waiting + parent training. School-age moderate/severe → medication ± behavioural therapy. Adults → medication first-line.

  3. Stimulants are first-line and the most effective treatment in all of psychiatry (effect size 1.0). Methylphenidate is the most commonly used. MoA: blocks DAT and NET → ↑ DA and NA in PFC → improved executive function.

  4. Atomoxetine (NRI, effect size 0.7) is 2nd-line: preferred when there is family history of substance abuse, tic disorder, or stimulant intolerance. Takes 4–6 weeks to work. Rare hepatotoxicity (1/50,000).

  5. Alpha-2 agonists (clonidine, guanfacine) are 3rd-line or adjunctive: useful for comorbid tics and stimulant-induced insomnia. Must taper — do not stop abruptly (rebound hypertension).

  6. PMT is the most effective behavioural therapy: uses positive reinforcement, time-out, response cost, and behaviour modelling.

  7. School accommodations are a right: ADHD is a SEN under HK inclusion education policy. Structured routines, token systems, daily report cards, and organisation skills teaching are key.

  8. Monitor: Height, weight, BP, HR, side effects, and academic/social function at every visit. Annual medication review with consideration of trial off medication.

  9. Comorbidities must be managed concurrently: ODD → PMT + stimulants; Anxiety → consider atomoxetine or add SSRI; Tics → atomoxetine or alpha-2 agonist preferred; SA risk → non-stimulant or long-acting formulation.

  10. Stimulant side effects to know: ↓ appetite/weight, insomnia (avoid late dosing), growth deceleration, irritability/rebound, ↑ tics, ↑ HR/BP.

High Yield Summary

  1. ADHD complications are cumulative and progressive: Academic failure → low self-esteem → social rejection → substance use → occupational failure → relationship breakdown → depression. Early treatment interrupts this cascade.

  2. Childhood complications: Academic underachievement, behavioural problems, peer rejection, poor self-esteem, injuries from recklessness.

  3. Adolescent complications: School dropout, legal issues (especially with comorbid CD), substance use initiation, reckless driving, relationship problems, injuries.

  4. Adult complications: Occupational failure, chronic self-esteem issues, relationship instability, substance abuse, mood disorders, injuries/accidents.

  5. Worst trajectory: ADHD + ODD → CD → Antisocial Personality Disorder + substance abuse + criminality. Comorbid CD is the strongest poor prognostic factor.

  6. Stimulant complications: ↓ appetite/weight, growth deceleration, insomnia, irritability/rebound, ↑ tics, tachycardia, rare psychosis, abuse potential. Avoid dosing after 5–6pm.

  7. Atomoxetine complications: GI upset, sedation, mood changes, rare hepatotoxicity (1/50,000), suicidal ideation (FDA black box warning).

  8. Alpha-2 agonist complications: Sedation, hypotension, bradycardia, rebound hypertension if stopped abruptly — always taper.

  9. Psychosocial burden: Family stress, financial cost, stigma (particularly relevant in HK Chinese culture), educational system strain.

  10. Prognosis: ~50% retain criteria in adolescence; ~40–60% have adult problems; remission is most likely for hyperactivity, least likely for inattention.

On this page

No Headings